Recruiting

COmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Melanoma is an aggressive and potentially fatal skin cancer and was the fifth most commonly diagnosed cancer among both men and women in the United States in 2022. When detected early, cutaneous melanoma has a favorable prognosis, with a 5-year survival rate exceeding 90%. Because melanoma frequently affects younger patients, wide local excision according to international guidelines may result in substantial functional and aesthetic morbidity. Reconstruction is therefore a critical component of locoregional management and should aim to optimize functional and aesthetic outcomes without compromising oncologic control. To date, no consensus exists regarding the optimal reconstructive strategy. Skin grafts are often favored for their presumed ability to facilitate early detection of local recurrence but are associated with donor-site morbidity and suboptimal morphofunctional outcomes. Flap reconstruction has been reported to improve healing time and aesthetic results; however, it is not commonly considered first-line after melanoma excision, largely due to the unsubstantiated concern that flaps may delay recurrence detection. Notably, objective data supporting this concern are lacking. Only two retrospective studies have addressed this issue. The largest, including 165 patients, reported that perforator-based pedicled flaps achieved favorable functional and aesthetic outcomes without adversely affecting locoregional disease control. A smaller study of facial melanoma similarly found immediate reconstruction with a facial artery perforator flap to be safe and aesthetically satisfactory. In our institution, both skin grafts and flap reconstructions are used following multidisciplinary discussion. We therefore aim to comparatively evaluate wound healing after margin re-excision and patient-reported quality of life following melanoma excision, regardless of tumor stage or location, to determine whether one reconstructive approach provides superior clinical or functional benefit in routine practice.

Condition: Stage II Cutaneous Melanoma
Sponsor: Nantes University Hospital

Who can join

Age: 18 years and older
Sex: All sexes
Healthy volunteers: Not accepted

Inclusion 5

Minimum age: 18 years
Study condition: Stage II Cutaneous Melanoma
Adult men or women (≥ 18 years)
Patients with cutaneous melanoma of any stage (I, II, or III) according to the AJCC Cancer Staging Manual, 8th edition (2017), diagnosed prior to surgery
Non-closable surgical defect after margin re-excision

Exclusion 6

Patients with microscopic or macroscopic nodal involvement when the sentinel lymph node has been removed
Patients with distant metastases identified on ultrasound and/or CT scan and/or PET-CT, when performed
Surgical contraindication to perforator flap reconstruction
Pregnant or breastfeeding women
Patients without health insurance coverage
Vulnerable individuals: persons deprived of liberty, under legal guardianship, or under curatorship

Where

1 site, 1 recruiting

CHU Nantes-Department of Severe Burns and Aesthetic Surgery

Nantes, Nantes, France

Recruiting

Contact

Ugo Lancien, MD

02 40 08 73 04 ugo.lancien@chu-nantes.fr
Alexandra Poinas, PhD

+33 2 53 48 28 57 alexandra.poinas@chu-nantes.fr

Potential match only. Final eligibility is determined by the study team.